Dr. Alya Al Mazrouei, Acting Executive Director, ICLDC

Abu Dhabi, United Arab Emirates: Mubadala Health’s Imperial College London Diabetes Centre (ICLDC) has become the first in Abu Dhabi and the third in the UAE to be accredited as a Collaborating Centre for Obesity Management (COM) by the European Association for the Study of Obesity (EASO).

Under the EASO COM scheme, obesity management centres are accredited against a set of stringent criteria and in accordance with accepted European and academic guidelines to ensure consistently high standards in different countries across the world.

The EASO Obesity Management Task Force completed its assessment of ICLDC and granted it an initial two-year EASO International Affiliate COM status from 1 April this year. In addition, the body has recognised two of ICLDC’s experts – Dr Mohgah El Sheikh and Dr Matthew Allum, both consultant endocrinologists and diabetologists – as EASO National Clinical Fellows.

ICLDC Acting Executive Director, Dr. Alya Al Mazrouei, says: “We are delighted to have received this recognition, which affirms our expertise in managing obesity alongside diabetes. In addition, it is the goal of Mubadala Health and ICLDC to offer world-class services to the UAE and region, and this successful evaluation of our standards and our experts by the EASO task force proves that we are accomplishing this.”

It is estimated that over 37% of adults in the UAE are living with obesity and its presence is closely linked with a large number of health conditions, including heart disease and type 2 diabetes.  

Dr. El Sheikh, who is also ICLDC’s clinical lead for obesity and metabolic surgery, says: “Obesity is believed to account for 80-85% of the risk of developing type 2 diabetes, while research suggests that people with obesity can more than halve their risk of developing type 2 diabetes by losing 5-10% of their body weight.” 

Dr. Al Mazrouei adds that in addition to the treatment of obesity through dietary approaches, medication and addressing underlying conditions, ICLDC also works closely with the bariatric surgeons at its fellow Mubadala partner, Healthpoint, which is accredited as a Centre of Excellence by another international body, the Surgical Review Corporation.

Of these international accreditations, Dr. Al Mazrouei explains, “Obesity is a global epidemic with serious health, economic and social consequences, so it is important for countries to work together and share knowledge to ensure a consistent and optimal approach is adopted. As such, it is important for ICLDC to work with organizations such as EASO and the World Obesity Federation on projects that include raising international awareness and formulating guidelines to tackle obesity,” Dr. Al Mazrouei says.

Dr. El Sheikh agrees and adds that as a member of the EASO COM network, ICLDC will also have the opportunity to assist the network in its objective of developing consensus guidelines on several obesity management issues.

She welcomes this, having been one of the ICLDC physicians who contributed to the World Obesity Federation’s GCC and Lebanon Obesity Management Guidelines last year. “We are looking forward to sharing our in-depth regional knowledge with the European obesity centres, and look forward to learning from them as well,” she says.

About Mubadala Health:

Mubadala Health is the integrated healthcare network of Mubadala Investment Company. Established 2021, Mubadala Health operates, manages, and develops a portfolio of healthcare assets including: Abu Dhabi Telemedicine Centre (ADTC), Amana Healthcare, Capital Health Screening Centre (CHSC), Healthpoint, Imperial College London Diabetes Centre (ICLDC), and National Reference Laboratory (NRL). In addition, Cleveland Clinic Abu Dhabi is an integral part of Mubadala Health. With a vision to transform the regional healthcare landscape, Mubadala Health sets a new benchmark for the UAE and regional healthcare industry through its state-of-the-art facilities and world-class caregivers who strive to put patients first across its continuum of care. Innovation, research, and education are the foundational pillars of Mubadala Health, supporting the further development of a sustainable healthcare sector in line with the vision of Abu Dhabi and the region.

Mubadala Health is on Twitter, Instagram, Facebook and LinkedIn with the handle: @mubadalahealth.

About Imperial College London Diabetes Centre:

Imperial College London Diabetes Centre (ICLDC), a Mubadala Health partner, is a state-of-the-art outpatient facility that specialises in diabetes treatment, research, training and public health awareness. In just over a decade, the Centre has gained international renown for its holistic approach to the treatment of diabetes and related complications that enables patients to receive the full spectrum of care they need in one place.

With more than 80 diabetes professionals and endocrinologists under one roof, ICLDC offers best-in-class medical attention from first diagnosis to disease management across 11 specialist practice areas including adult and paediatric endocrinology, treatment of metabolic and electrolyte disorders, pre- and post-bariatric surgery care, heart disease prevention, nutritional advice, diabetes education services, ophthalmology, nephrology and podiatry.

ICLDC was established in 2006 in Abu Dhabi by Mubadala in partnership with the UK’s Imperial College London to address the growing demand for diabetes care in the UAE. The centre now operates three branches across Abu Dhabi and Al Ain, touching the lives of more than one million people through patient-centric programmes and public health initiatives. In 2007, ICLDC launched Diabetes. Knowledge. Action, now the longest running public health awareness campaign in the country. The initiative promotes an active lifestyle through an ongoing calendar of events for the whole community – Major activations include an annual walkathon that coincides with the World Diabetes Day in November.